The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform

Giovanni Pantini - One of the best experts on this subject based on the ideXlab platform.

  • perfluoropolyether phosphate Skin Exfoliation after a topical pre treatment tewl and Skin elasticity by in vivo non invasive methods
    International Journal of Cosmetic Science, 2007
    Co-Authors: Carmine Ostacolo, Antonia Sacchi, Antonietta Bernardi, Sonia Laneri, A. Brunetta, Giovanni Pantini
    Abstract:

    Glycolic acid (GA) and other alpha-hydroxyacids (AHAs) are common ingredients of products designed to accelerate Exfoliation of the Skin. It is known that acidic pHs are essential in order to increase the efficacy of AHA-based products. The formulator is, therefore, obliged to achieve a difficult balance between performance (Skin Exfoliation) and risks (Skin irritation). In order to overcome this problem, many common organic acids, and combinations of them, have been proposed, with marginal improvements. The need for a new chemistry, in order to achieve better results, was evident, particularly from the point of view of safety. We decided, therefore, to investigate the efficacy of perfluoropolyether (PFPE) phosphate, a new acidic material, already proposed for lowering the pH without increasing Skin irritation. Two gels containing PFPE phosphate at different pH values (3 and 7), an acidic gel containing GA at pH 3, and a neutral gel, without an active compound, were applied on 20 healthy volunteers and evaluated with regard to effects on the Skin: *Exfoliation after a topical pre-treatment with these gels *Transepidermal water loss (TEWL) and elasticity The main conclusion of the investigation was that PFPE phosphate has effects, particularly Skin Exfoliation rate, quite independent of the pH, and comparable to the gel containing GA at pH 3, apparently without the typical drawbacks of AHAs.

  • Perfluoropolyether phosphate: Skin Exfoliation after a topical pre‐treatment, TEWL and Skin elasticity, by in‐vivo non‐invasive methods
    International Journal of Cosmetic Science, 2007
    Co-Authors: Carmine Ostacolo, Antonia Sacchi, Antonietta Bernardi, Sonia Laneri, A. Brunetta, Giovanni Pantini
    Abstract:

    Glycolic acid (GA) and other alpha-hydroxyacids (AHAs) are common ingredients of products designed to accelerate Exfoliation of the Skin. It is known that acidic pHs are essential in order to increase the efficacy of AHA-based products. The formulator is, therefore, obliged to achieve a difficult balance between performance (Skin Exfoliation) and risks (Skin irritation). In order to overcome this problem, many common organic acids, and combinations of them, have been proposed, with marginal improvements. The need for a new chemistry, in order to achieve better results, was evident, particularly from the point of view of safety. We decided, therefore, to investigate the efficacy of perfluoropolyether (PFPE) phosphate, a new acidic material, already proposed for lowering the pH without increasing Skin irritation. Two gels containing PFPE phosphate at different pH values (3 and 7), an acidic gel containing GA at pH 3, and a neutral gel, without an active compound, were applied on 20 healthy volunteers and evaluated with regard to effects on the Skin: *Exfoliation after a topical pre-treatment with these gels *Transepidermal water loss (TEWL) and elasticity The main conclusion of the investigation was that PFPE phosphate has effects, particularly Skin Exfoliation rate, quite independent of the pH, and comparable to the gel containing GA at pH 3, apparently without the typical drawbacks of AHAs.

Ming Tao Cheng - One of the best experts on this subject based on the ideXlab platform.

Nubia Seyffert - One of the best experts on this subject based on the ideXlab platform.

  • Exfoliative toxin e, a new Staphylococcus aureusvirulence factor with host-specific activity
    Scientific Reports, 2019
    Co-Authors: Ichiro Imanishi, Ricardo Barros Mariutti, Eric Guédon, Sergine Even, Nadia Berkova, Raghuvir K. Arni, Ana-carolina Barbosa Caetano, Luiz De Paula Castro, Natayme Rocha Tartaglia, Nubia Seyffert
    Abstract:

    Exfoliative toxins (ETs) are secreted virulence factors produced by staphylococci. These serine proteases specifically cleave desmoglein 1 (Dsg1) in mammals and are key elements in staphylococcal Skin infections. We recently identified a new et gene in S. aureus O46, a strain isolated from ovine mastitis. In the present study, we characterized the new et gene at a genetic level and the enzymatic activity of the deduced protein. The S. aureus O46 genome was re-assembled, annotated and compared with other publicly available S. aureus genomes. The deduced amino acid sequence of the new et gene shared 40%, 53% and 59% sequence identity to those of ETA, ETB and ETD, respectively. The new et gene shared the same genetic vicinity and was similar in other S. aureus strains bearing this gene. The recombinant enzyme of the new et gene caused Skin Exfoliation in vivo in neonatal mice. The new et-gene was thus named ete, encoding a new type (type E) of exfoliative toxin. We showed that ETE degraded the extracellular segments of Dsg1 in murine, ovine and caprine epidermis, as well as in ovine teat canal epithelia, but not that in bovine epidermis. We further showed that it directly hydrolyzed human and swine Dsg1 as well as murine Dsg1α and Dsg1β, but not canine Dsg1 or murine Dsg1γ. Molecular modeling revealed a correlation between the preferred orientation of ETE docking on its Dsg1 cleavage site and species-specific cleavage activity, suggesting that the docking step preceding cleavage accounts for the ETE species-specificity. This new virulence factor may contribute to the bacterial colonization on the stratified epithelia in certain ruminants with mastitis.

Carmine Ostacolo - One of the best experts on this subject based on the ideXlab platform.

  • perfluoropolyether phosphate Skin Exfoliation after a topical pre treatment tewl and Skin elasticity by in vivo non invasive methods
    International Journal of Cosmetic Science, 2007
    Co-Authors: Carmine Ostacolo, Antonia Sacchi, Antonietta Bernardi, Sonia Laneri, A. Brunetta, Giovanni Pantini
    Abstract:

    Glycolic acid (GA) and other alpha-hydroxyacids (AHAs) are common ingredients of products designed to accelerate Exfoliation of the Skin. It is known that acidic pHs are essential in order to increase the efficacy of AHA-based products. The formulator is, therefore, obliged to achieve a difficult balance between performance (Skin Exfoliation) and risks (Skin irritation). In order to overcome this problem, many common organic acids, and combinations of them, have been proposed, with marginal improvements. The need for a new chemistry, in order to achieve better results, was evident, particularly from the point of view of safety. We decided, therefore, to investigate the efficacy of perfluoropolyether (PFPE) phosphate, a new acidic material, already proposed for lowering the pH without increasing Skin irritation. Two gels containing PFPE phosphate at different pH values (3 and 7), an acidic gel containing GA at pH 3, and a neutral gel, without an active compound, were applied on 20 healthy volunteers and evaluated with regard to effects on the Skin: *Exfoliation after a topical pre-treatment with these gels *Transepidermal water loss (TEWL) and elasticity The main conclusion of the investigation was that PFPE phosphate has effects, particularly Skin Exfoliation rate, quite independent of the pH, and comparable to the gel containing GA at pH 3, apparently without the typical drawbacks of AHAs.

  • Perfluoropolyether phosphate: Skin Exfoliation after a topical pre‐treatment, TEWL and Skin elasticity, by in‐vivo non‐invasive methods
    International Journal of Cosmetic Science, 2007
    Co-Authors: Carmine Ostacolo, Antonia Sacchi, Antonietta Bernardi, Sonia Laneri, A. Brunetta, Giovanni Pantini
    Abstract:

    Glycolic acid (GA) and other alpha-hydroxyacids (AHAs) are common ingredients of products designed to accelerate Exfoliation of the Skin. It is known that acidic pHs are essential in order to increase the efficacy of AHA-based products. The formulator is, therefore, obliged to achieve a difficult balance between performance (Skin Exfoliation) and risks (Skin irritation). In order to overcome this problem, many common organic acids, and combinations of them, have been proposed, with marginal improvements. The need for a new chemistry, in order to achieve better results, was evident, particularly from the point of view of safety. We decided, therefore, to investigate the efficacy of perfluoropolyether (PFPE) phosphate, a new acidic material, already proposed for lowering the pH without increasing Skin irritation. Two gels containing PFPE phosphate at different pH values (3 and 7), an acidic gel containing GA at pH 3, and a neutral gel, without an active compound, were applied on 20 healthy volunteers and evaluated with regard to effects on the Skin: *Exfoliation after a topical pre-treatment with these gels *Transepidermal water loss (TEWL) and elasticity The main conclusion of the investigation was that PFPE phosphate has effects, particularly Skin Exfoliation rate, quite independent of the pH, and comparable to the gel containing GA at pH 3, apparently without the typical drawbacks of AHAs.

Gautam Borthakur - One of the best experts on this subject based on the ideXlab platform.

  • patterns of non hematological adverse effects in patients with chronic myeloid leukemia in chronic phase cml cp treated with ponatinib experience at a single institution
    Blood, 2013
    Co-Authors: Hagop M Kantarjian, Carlos Guillermo Romo, Alfonso Quintascardama, Elias Jabbour, Marylou Cardenasturanzas, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M Kadia, Gautam Borthakur
    Abstract:

    Introduction Ponatinib is a multi-targeted tyrosine kinase inhibitor (TKI) efficacious in pts with refractory CML. Ponatinib inhibits other tyrosine kinases (e.g. RET, FGFR, FLT3) that may lead to off target adverse effects (AE). We report a single-institution experience of frequencies of non-hematological AE among pts on therapy with ponatinib. Methods A total of 90 pts with CML-CP[49 relapsed refractory (RR), 41 frontline] treated at our institution on clinical trials with ponatinib were analyzed. AE were recorded on each pt visit and charts were reviewed for AE and risk factors. Results For RR pts (n=49)the starting dose of ponatinib was 45 mg in 42 (86%) pts. 39 (80%) had dose interruptions, due in 17 (44%) to grade 3 thrombocytopenia and in 22 (56%) to non-hematological AE (elevated pancreatic enzymes 7 pts of whom 5 had pancreatitis; body aches and headache 7; hypertension 7; Skin toxicity 5; fatigue 5). 35 pts (71%) had dose reduction to 30 or 15 mg. Hypertension (H.T.) stage 2 (≥160/100 mm Hg) occurred in 15 (31%) pts; only 2 of new onset. Blood pressure was controlled in all with antihypertensives. Other cardiovascular AE included QTc prolongation in 1 pt, atrial fibrillation in 1 pt, acute myocardial infarction in 3, venous thrombosis in 3, arterial thrombosis in 4, transient ischemic attack (TIA) in 1 and Raynaud’s in 1. No pt discontinued ponatinib due to cardiovascular AE’s. Symptomatic pancreatitis developed in 8 pts (16%). Grade 3/4 elevations in serum lipase and amylase occurred in 12 (24%) pts and 2 (4%) pts respectively. Median days to onset of pancreatitis was 24 (range 7-456). 27 pts (55%) developed cutaneous toxicity including xerosis/dry Skin in 10 (37%) and grade 3 erythroderma and Exfoliation of the Skin in 5. Four pts died, none related to ponatinib. 13 pts went off the study: 5 went to SCT, 3 progressed, 1 pt died in CCyR of multiple co-morbidities, 1 pt had progressive melanoma, 1 pt was transferred to another hospital, and 2 for ponatinib-related AE (headache in 1 and headache, fatigue, depression, and abdominal pain in 1). For pts in frontline setting (n=41) the starting dose was 45 mg in all. 29 pts (71%) had dose interruptions due to one or more of the following: grade 3/4 pancreatic enzyme elevation in 16, myelosuppression in 4, and various non-hematological AE in 15 (Skin toxicity in 4, fatigue in 2, headache in 1, chest pain in 2, elevated liver enzymes in 2, suspected seizure vs. TIA in 1, grade 3 diarrhea in 1, memory disturbances in 1, and grade 3 hypertension in 1, erectile dysfunction in 1). 24 pts (59%) had dose reduction, from 45 mg to 30 mg in 20 pts and then to 15 mg in 4 pts. H.T. stage 2 occurred in 3 (7%) pts usually among patients with pre-existing H.T. Other cardiovascular AE included grade 2 QTc prolongation in 1 pt, possible TIA vs. possible seizure in 1, and Raynaud’s in 2. Pancreatitis was seen in 12 pts (29%) with grade 1-2 and 6 pts (15%) with grade 3/4. Grade 3/4 lipase/amylase elevations occurred in 16 (39%) and 3 (7%) pts. Median days to the onset of pancreatitis were 6 (4-22). 34 pts (83%) developed Skin toxicity with rash (any grade) in 25 pts (61%), xerosis/dry Skin in 18 pts (44%) and grade 3 erythroderma and Skin Exfoliation in 2 (pts may have had ≥1 type of Skin AE). 2 pts discontinued therapy, due to severe xerosis in 1 and recurrent gra 4 neutropenia in another. 1 pt developed grade 2 pericarditis possibly related to ponatinib. For all the 90 pts, risk factors for cardiovascular and pancreatic toxicities included 20 (22%) smokers, 2 heavy alcohol consumers, 27 (30%) obese (BMI ≥30 Kg/m2), 30 (33%) with hypertriglyceridemia, 17 (19%) had hypercholesterolemia and 10 pts were receiving lipid lowering therapies. Conclusions Ponatinib is generally well tolerated and AEs can usually be properly managed. AE are more common in RR pts with greater frequency of hypertension, cardiovascular complications, headache, dry mouth and dose interruptions. Most pts are able to continue therapy after dose adjustments. Disclosures: Kantarjian: ARIAD: Research Funding. Cortes: Ariad, Pfizer, Teva: Consultancy; Ariad, BMS, Novartis, Pfizer, Teva: Research Funding.